This task order is for the evaluation of safety and immunogenicity of live-attenuated pediatric RSV vaccine candidate DNS/D1313/I1334L, delivered as nasal spray.
Ended Awarded Last action
- Contract number
- 75N93020F00002
- Awardee
-
The Johns Hopkins University UEI FTMTDMBR29C7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $79,824
Award facts
- Opportunity
-
- Operation of a Facility for the Study of Infectious Agents, Vaccines and Antivirals in Adult and Pediatric Human Subjects Solicitation · Posted Sep 12, 2018
- Contract value 100% obligated
- $79,824.41 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Baltimore, MD 21218, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$853,869 | |
| Other Administrative Action | $0 | |
| Original award | $933,693 |
About this award
This federal contract was awarded by the Department of Health and Human Services' National Institutes of Health, National Institute of Allergy and Infectious Diseases, to The Johns Hopkins University as the prime contractor. The task order is for the evaluation of safety and immunogenicity of a live-attenuated pediatric respiratory syncytial virus (RSV) vaccine candidate, delivered as a nasal spray. The contract has a total potential value of $79,824.41 and a completion date of December 30, 2021. It is a cost-no-fee delivery order contract.
The prime contractor, The Johns Hopkins University, is a private research university with extensive experience supporting federal biomedical research efforts. Major subcontractors on this contract include Vanderbilt University Medical Center and the University of Rochester, who will conduct Phase I clinical studies on bivalent live-attenuated human parainfluenza virus type 3 (HPIV3) and human metapneumovirus (HMPV) vaccines in seronegative children and infants. The contract does not utilize any set-aside designations.
Quick answers
Who was awarded contract 75N93020F00002?
75N93020F00002 was awarded to The Johns Hopkins University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on March 15, 2020.
How much is contract 75N93020F00002 worth?
The government has obligated $79,824 on 75N93020F00002.
Is contract 75N93020F00002 an order under another contract?
Yes. 75N93020F00002 is a delivery order under 75N93019D00031, an indefinite delivery contract.
Was contract 75N93020F00002 competed?
The extent of competition for 75N93020F00002 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award